Bruker (NASDAQ:BRKR) Downgraded by Wolfe Research to “Peer Perform”

Wolfe Research downgraded shares of Bruker (NASDAQ:BRKR) from an outperform rating to a peer perform rating in a research report sent to investors on Monday, MarketBeat Ratings reports.

BRKR has been the topic of a number of other reports. TD Cowen lowered their price target on shares of Bruker from $74.00 to $72.00 and set a hold rating on the stock in a research report on Wednesday, August 7th. The Goldman Sachs Group decreased their target price on shares of Bruker from $72.00 to $60.00 and set a sell rating on the stock in a report on Tuesday, July 9th. Jefferies Financial Group initiated coverage on shares of Bruker in a report on Monday, June 3rd. They issued a buy rating and a $85.00 price objective on the stock. Citigroup decreased their price objective on shares of Bruker from $95.00 to $80.00 and set a buy rating on the stock in a report on Wednesday, July 10th. Finally, Wells Fargo & Company initiated coverage on shares of Bruker in a report on Tuesday, August 27th. They issued an overweight rating and a $78.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Bruker presently has an average rating of Hold and a consensus target price of $81.40.

Bruker Trading Down 2.3 %

NASDAQ:BRKR opened at $69.06 on Monday. Bruker has a 12 month low of $53.79 and a 12 month high of $94.86. The firm has a fifty day simple moving average of $65.20 and a 200-day simple moving average of $71.66. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $10.04 billion, a P/E ratio of 25.11, a PEG ratio of 2.43 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.52. The company had revenue of $800.70 million during the quarter, compared to the consensus estimate of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.50 earnings per share. On average, equities research analysts anticipate that Bruker will post 2.61 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Monday, September 2nd were given a dividend of $0.05 per share. The ex-dividend date was Friday, August 30th. This represents a $0.20 dividend on an annualized basis and a yield of 0.29%. Bruker’s dividend payout ratio (DPR) is 7.27%.

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently made changes to their positions in BRKR. Centaurus Financial Inc. acquired a new position in shares of Bruker during the second quarter valued at $291,000. Sanctuary Advisors LLC acquired a new stake in Bruker in the second quarter worth about $296,000. Gordian Capital Singapore Pte Ltd acquired a new stake in Bruker in the second quarter worth about $52,000. Maven Securities LTD lifted its holdings in Bruker by 400.0% in the second quarter. Maven Securities LTD now owns 20,000 shares of the medical research company’s stock worth $1,276,000 after purchasing an additional 16,000 shares during the period. Finally, Aristides Capital LLC acquired a new stake in Bruker in the 2nd quarter valued at about $222,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.